In May 2008, the U.S. Food and Drug Administration (FDA) unveiled the Sentinel Initiative – a national electronic data system designed to track the safety of drugs, biologics, and medical devices in the United States. Since that time, FDA has engaged key stakeholders to address technical and policy issues that are critical to the initiative’s success.
On January 12, the Engelberg Center for Health Care Reform hosted the third annual Sentinel Initiative public workshop, bringing together the stakeholder community for a discussion on a variety of topics in active medical product surveillance, including an update on Mini-Sentinel, the testing mechanism and coordinating center for the Sentinel Initiative; near-term plans for the Sentinel Initiative; and opportunities for coordination with other Department of Health and Human Services efforts that use distributed systems of automated health care data.
Read The New England Journal of Medicine article, “Developing the Sentinel System – A National Resource for Evidence Development.”
Agenda
-
January 12
-
9:00 AM -- Welcome
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityJanet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration -
9:10 AM -- Keynote Address
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University -
9:40 AM -- Sentinel Today: FDA Perspective
Rachel Behrman Director, Office of Medical Policy, Center for Drug Evaluation and ResearchJudy Racoosin Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research -
10:00 AM -- Session I: Mini-Sentinel Accomplishments and Plans for Year Two
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityRichard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care InstituteLesley Huntley Curtis Associate Professor in Medicine - Duke University School of MedicineKristen B. Rosati Coppersmith Schermer & Brockelman PLC -
1:15 PM -- Session II: Perspectives from the Stakeholder Community
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityKathleen Jaeger Vice President and Chief Executive OfficerMyrl Weinberg Chief Executive Officer - National Health CouncilDiana Zuckerman National Research Center for Women & Families/Cancer Prevention and Treatment FundDan Troy Senior Vice President and General CounselJ. Leonard Lichtenfeld Deputy Chief Medical Officer, American Cancer Society -
3:00 PM -- Session III: Sentinel as a National Resource for Evidence Development
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityJanet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug AdministrationModerator: Reed Tuckson UnitedHealth GroupSam Nussbaum Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc. -
4:30 PM -- Closing Remarks
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
-